Iteos Therapeutics Alpha and Beta Analysis

ITOSDelisted Stock  USD 10.15  0.00  0.00%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Iteos Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Iteos Therapeutics over a specified time horizon. Remember, high Iteos Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Iteos Therapeutics' market risk premium analysis include:
Beta
(0.01)
Alpha
0.00569
Risk
0.0
Sharpe Ratio
0.0
Expected Return
0.0
Please note that although Iteos Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Iteos Therapeutics did 0.01  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Iteos Therapeutics stock's relative risk over its benchmark. Iteos Therapeutics has a beta of 0.01  . As returns on the market increase, returns on owning Iteos Therapeutics are expected to decrease at a much lower rate. During the bear market, Iteos Therapeutics is likely to outperform the market. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Iteos Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Iteos Therapeutics market risk premium is the additional return an investor will receive from holding Iteos Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Iteos Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Iteos Therapeutics' performance over market.
α0.01   β-0.0097

Iteos Therapeutics Fundamentals Vs Peers

Comparing Iteos Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Iteos Therapeutics' direct or indirect competition across all of the common fundamentals between Iteos Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Iteos Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Iteos Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Iteos Therapeutics to competition
FundamentalsIteos TherapeuticsPeer Average
Return On Equity-0.35-0.31
Return On Asset-0.18-0.14
Current Valuation(61.62 M)16.62 B
Shares Outstanding44.21 M571.82 M
Shares Owned By Insiders0.34 %10.09 %
Shares Owned By Institutions90.28 %39.21 %
Number Of Shares Shorted2.06 M4.71 M

Iteos Therapeutics Opportunities

Iteos Therapeutics Return and Market Media

The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Is iTeos Therapeutics Inc. a good long term investment - Free Capital Allocation Plans - Jammu Links News
07/18/2025
2
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
07/22/2025
3
Readystate Asset Management LP Sells 26,114 Shares of iTeos Therapeutics, Inc.
07/25/2025
4
iTeos Therapeutics Expected to Announce Quarterly Earnings on Thursday
08/12/2025
5
Can iTeos Therapeutics Inc. sustain earnings growth - Market Sentiment Summary Entry Point Confirmation Alerts -
08/21/2025
6
iTeos Therapeutics Inc. stock trend outlook and recovery path - Dividend Hike Verified Trade Idea Suggestions - Newser
08/25/2025
7
Disposition of 900000 shares by Ra Capital Management, L.p. of Iteos Therapeutics subject to Rule 16b-3
08/28/2025

About Iteos Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Iteos or other delisted stocks. Alpha measures the amount that position in Iteos Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Iteos Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Iteos Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iteos Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Iteos Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Iteos Therapeutics. Please utilize our Beneish M Score to check the likelihood of Iteos Therapeutics' management manipulating its earnings.
20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Iteos Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Consideration for investing in Iteos Stock

If you are still planning to invest in Iteos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Iteos Therapeutics' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum